SPTX logo

SEAPORT THERAPEUTICS INC

SPTXNASDAQ
🏆 #2443 by market capEarnings Nov 2US Equity
$19.00▼ $0.56 (−2.96%)
Live
🔔
Track SPTX
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 3.0%
7d▼ 14.4%
14d▼ 17.2%
30d▼ 22.4%
ytd—
1y—
🏦Market Cap
$1.02B
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
52
Weak

Trading Snapshot

Day Range
$18.80 – $19.08
52-Week Range
$14.85 – $28.38
Volume
$3.73B
Avg Volume
$3.32B
Shares Outstanding
53.5M
Next Earnings
Nov 11, 2026

Fundamentals Snapshot

Annual Revenue
$116M
Last Q Revenue
$29M
P/E Ratio
—
P/S Ratio
—
EPS (TTM)
$-1.65
Dividend Yield
—

Why Investors Own SPTX

  • ✓High-growth profile — revenue up -8.5% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 56% gross margin and 9% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

SPTX logo

SEAPORT THERAPEUTICS INC

SPTX
Financial Trends
Revenue (TTM)The total money the company brought in from sales, before subtracting any costs.
$116M▼ −5.3% YoY
Gross Margin (TTM)Of every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
56.1%▲ +3.5% YoY
Operating Income (TTM)Profit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$20M▼ −5.3% YoY
Free Cash Flow (TTM)Cash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$10M▼ −5.3% YoY
StockOtter · stockotter.space

About SEAPORT THERAPEUTICS INC

Seaport Therapeutics, Inc. is a developing biopharmaceutical enterprise currently undergoing clinical trials, focused on creating groundbreaking treatments for neuropsychiatric conditions. The company is primarily engaged in tackling disorders like depression and anxiety, utilizing its unique Glyph technology. This exclusive platform is engineered to allow for oral administration of drugs, circumventing initial metabolic processing in the liver, and thereby reducing the risk of liver enzyme elevations, hepatotoxicity, and other potential adverse reactions. Every therapeutic agent in their pipeline incorporates this advanced platform, with all research and development efforts exclusively dedicated to neuropsychiatric applications. Founded in 2024 and situated in Boston, Massachusetts, the company connects with medical professionals and influential experts across the healthcare and neuropsychiatric sectors.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
52/100

Analyst Price Target

ⓘ
Average Target
$21.45
▲ +12.9% Upside
High Target$26.60
Low Target$19.31
Based on 35 analysts

Latest News & Updates

🚀
MarketWatch·2h ago

SEAPORT THERAPEUTICS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
MarketWatch·5h ago

Analysts lift SPTX price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Bloomberg·1d ago

SEAPORT THERAPEUTICS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.